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Abstract
Background: Recently, phage display technology has made it possible to define the circulating repertoire of
humoral immunity. This study was designed to define the circulating antibodies specific to centenarians.
Results: We used a phage-displayed combinatorial peptide library to screen for peptides (YSATLRY and
YSPTLFY) that preferentially react with the IgG fraction of centenarians aged 100–105 years. Centenarian sera
binds to YSATLRY and YSPTLFY with higher frequency than that of healthy volunteers aged 60–79 years or
healthy volunteers younger than or equal to 43 years of age. We prepared polyclonal antibodies to YSATLRY
from human sera to immunoprecipitate the native antigen, which was identified as the carboxy-terminal
domain (CTD) of DNA-directed RNA polymerase II subunit RPB1. The RBP1 CTD contains multiple YSPTSPS
repeats, which are significantly homologous to YSATLRY and YSPTLFY. The immunoprecipitated RPB1 had
significantly slower mobility than did RPB1 in cell lysates, and the polyclonal antibodies reacted with CTD
peptide, depending on the phosphorylation pattern. Therefore, it appears that the polyclonal antibodies
preferentially bind to highly phosphorylated RPB1. We also confirmed that human monoclonal antibodies
reactive to both YSATLRY and YSPTLFY bound to the phosphorylated YSPTSPS motif.
Conclusions: This study showed that centenarians possess IgG antibodies that are reactive to YSATLRY and
YSPTLFY, mimicking the phosphorylated form of the YSPTSPS motif (CTD of RPB1), at a much higher
frequency than that of the average population.
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Findings
Humoral immunity has evolved to protect the host. For
an individual, it is one of the greatest biological advan-
tages to harbor an effective repertoire of humoral
immunity against hostile agents like bacteria, viruses, or
cancers [1]. There has been a long-standing question
whether centenarians possess a special humoral immun-
ity repertoire that enables longer survival than that of
the general population. A phage-displayed combinatorial
peptide library made it possible to enrich for antibody-
reactive peptides [2]. These peptide sequences can be
used to identify specific antigens. In this study, we used
a phage-displayed combinatorial peptide library to
screen for peptides that preferentially react to the IgG
fraction of centenarians and identified the antigen mim-
icked by these peptides.
The sera of three populations were collected, including
45 centenarians aged 100–105 years (defined as the cen-
tenarian group), 25 healthy volunteers aged 60–79 years
(defined as the old group), and 25 healthy volunteers
younger than or equal to 43 years (defined as the young
group) (Additional file 1: Table S1). IgG fractions were
purified from the centenarian sera by protein G column
chromatography, and these fractions were used to enrich
phage from the phage-displayed combinatorial peptide
library through biopanning (Additional file 2). After the
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final round of biopanning, phages that were preferen-
tially reactive to the centenarian IgG pool were se-
lected by a phage enzyme immunoassay. Phage clones
encoding two highly homologous peptides with
YSATLRY and YSPTLFY sequences were strongly
enriched in the samples, each of which comprised 20 %
of positive clones. These two peptides, either phage-
displayed or chemically synthesized and conjugated to
bovine serum albumin (BSA), reacted with individual
centenarian IgG fractions at a much higher frequency
than did IgG fractions of other individuals in the en-
zyme immunoassays (Fig. 1a and b). Each individual
centenarian’s antibody titers to these two peptides were
highly correlated; therefore, we hypothesized that these
two peptides actually represent the same antigen epi-
tope (Fig. 1c).
To prepare human polyclonal antibodies (pAbs) to
YSATLRY, we collected sera from 59 additional
healthy volunteers aged 20–40 years and performed
enzyme immunoassays to screen for those who had
antibodies to the two homologous peptides (Additional
file 3: Figure S1). Five volunteers exhibited significant anti-
body titers to both YSATLRY and YSPTLFY (Additional
file 3: Figure S1; volunteers #7, #11, #19, #47, and #50).
The pAbs were prepared from these sera using an
YSATLRYGGGSC-cross-linked affinity column, and the
pAb specificity to the peptides was confirmed by competi-
tion enzyme immunoassays (Additional file 4: Figure S2).
These results showed that pAb binding to the
YSATLRYGGGSC-BSA conjugate coated on microtiter
plates was competitively hindered by YSATLRYGGGS in
the soluble fraction.
We used the pAbs to identify the antigen by immu-
noprecipitation analysis and found that many human
cell lines contained antigen that was reactive to the
pAbs (data not shown). The pAbs prepared from vol-
unteers #47 (pAb 47) and #19 (pAb 19) immunopre-
cipitated three major protein bands from LoVo cell
lysates (Fig. 2a). The proteins were subjected to mass
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Fig. 1 Defining the humoral repertoire of centenarians with peptide mimotopes. a Microtiter plates were coated with anti-human IgG antibodies.
After blocking, sera from individual centenarians (Centenarian group), healthy volunteers aged 60–79 years (Old group), and healthy volunteers
younger than or equal to 43 years (Young group) were added to the wells. Phage-displaying peptide YSATLRY or YSPTLFY was added, and the
amount of bound phage was determined using the anti-M13 antibody HRP conjugate and ABTS substrate solution. (b) Microtiter plates were
coated with BSA-conjugated peptides (YSA = YSATLRYGGGSC, YSP = YSPTLFYGGGSC). After blocking, sera from individuals were added to each
well. After incubation and washing, HRP-conjugated anti-human IgG (H + L) antibodies and ABTS solution were added sequentially with
intermittent washing. * P < 0.05. (c) R-square calculation from the enzyme immunoassay result shown in B (R2 = 0.94)
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DNA-directed RNA polymerase II subunit RPB1 (largest
subunit of RNA polymerase II; NP_000928) and DNA-
directed RNA polymerase II subunit RPB2 isoform 1
(NP_000929). Both proteins are components of the RNA
polymerase II complex [3]; therefore, we concluded that
the pAbs immunoprecipitated part of the RNA polymer-
ase II complex. The pAbs reacted with protein that had a
similar molecular weight to RPB1 (Fig. 2b). We searched
RPB1 amino acid sequences homologous to YSATLRY
and YSPTLFY, and found that the RPB1 carboxy-terminal
domain (CTD) contains multiple YSPTSPS repeats, which
are significantly homologous to YSATLRY and YSPTLFY.
The identity of RPB1 was confirmed in immunoprecipita-
tion analysis using the pAbs and immunoblot analysis
with anti-RPB1 antibodies (Fig. 2b). Every residue of the
YSPTSPS motif can be phosphorylated except for proline
[4]; therefore, we tested the phosphorylation status of
immunoprecipitated RPB1 CTD using antibodies reactive
to YpSPTSPS (pS2-RPB1) and YSPTpSPS (pS5-RPB1).
Both antibodies reacted with the immunoprecipitates in
the immunoblot, indicating that all immunoprecipitated
RPB1 contained both YpSPTSPS and YSPTpSPS motifs
(Fig. 2b). Immunoprecipitated RPB1 had significantly
slower mobility than did RPB1 in cell lysates, suggesting
that the pAbs preferentially bind to highly phosphorylated
RPB1 [5, 6]. This preferential binding was confirmed in
enzyme immunoassays using conjugates of CTD peptide
and BSA (Additional file 5: Figure S3A). pAb 19 did not
react with YSPTSPSYSPTSPS (CTD-BSA), YSPTpSP-
SYSPTSPS (pS5-BSA), or YSPTpSPSYpSPTSPS (pS5S2-
BSA) (Additional file 5: Figure S3B). We hypothesized that
pAb 19 would bind to the YSPTSPS motif with a different
phosphorylation pattern.
To confirm that single antibody molecules reactive to
YSATLRY and YSPTLFY also bind to phosphorylated
YSPTSPS motifs, we generated monoclonal antibodies
(mAbs) from the B-lymphocyte pool of volunteer #19.
Briefly, a phage-displayed combinatorial single-chain
variable fragment (scFv) library with a complexity of
1.84 × 109 was constructed using mRNA prepared from
peripheral mononuclear cell fractions of volunteer #19.
Biopanning was performed on YSATLRY, and two clones
reactive to both YSATLRY and YSPTLFY were selected.
Then, two antibody clones were prepared as scFv-
human Fc fusion proteins as described previously [7].
The reactivity of the two mAbs (scFv-human Fc fusion
protein) was tested in enzyme immunoassays (Additional
file 5: Figure S3B). mAb 2 reacted with YSATLRY-BSA,
YSPTLFY-BSA, pS5-BSA, and pS5S2-BSA, but not with
nonphosphorylated CTD (CTD-BSA). This result con-
firmed that YSATLRY and YSPTLFY mimic the phos-
phorylated CTD motif. The mAb 1 clone did not react
with any of the CTD peptides, similar to pAb 19.
The reactivity of mAbs to RPB1 CTD was tested in
immunoprecipitation and immunoblot analyses. A band
with a molecular weight equivalent to RPB1 was
A Unnamed protein product [Homo sapiens]
B NP_000928, DNA-directed RNA polymerase II subunit RPB  1[Homo sapiens]
C NP_000929, DNA-directed RNA polymerase II subunit RPB2 isoform  1[Homo sapiens]
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Fig. 2 Identification of RPB1 as the antigen recognized by pAb 47, pAb 19, and mAbs. a LoVo cell lysates were immunoprecipitated with pAb 47
and pAb 19, and the immunoprecipitates were subjected to 4–12 % Bis-Tris gel electrophoresis. Gels were stained with Coomassie Brilliant Blue,
the bands were excised, and their identities were determined using mass spectrometry. (b) LoVo cell lysates were immunoprecipitated with pAb
or mAb (scFv-human Fc fusion protein). The resulting precipitates were subjected to immunoblot analysis with antibodies specific for RPB1 or
phosphorylated RPB1. Normal human pooled IgG fractions and LoVo cell lysates were used as controls
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visualized in lanes loaded with mAb 1 and mAb 2 im-
munoprecipitates (Additional file 6: Figure S4). The
identities of these protein bands were confirmed by im-
munoblot analysis (Fig. 2b). The antibodies that reacted
with RPB1 CTD (RPB1), YpSPTSPS (pS2-RPB1), and
YSPTpSPS (pS5-RPB1) all reacted with the protein band
(Additional file 4: Figure S2B).
In summary, this study showed that centenarians pos-
sess IgG antibodies that are reactive to YSATLRY and
YSPTLFY, mimicking the phosphorylated form of the
YSPTSPS motif (RPB1 CTD) at a much higher fre-
quency than the average population. RNA polymerase
has been reported to function as an autoantigen in
scleroderma patients [8–11]. It has also been suggested
that the repetitive amino acid sequence and high content
of charged residues in the RPB1 CTD structure contrib-
ute to its role as an autoantigen [12]. However, the life
expectancy of patients with scleroderma is not signifi-
cantly different from healthy individuals [13]. Currently,
it is not clear whether autoantibodies provide a protect-
ive function to centenarians. To determine whether the
subjects possessing IgG antibodies reactive to YSATLRY
and YSPTLFY had an overall tendency to produce auto-
antibodies, we tested antinuclear antibody (ANA) levels
in the sera of 45 centenarians and 25 old and 25 young
volunteers. Of these, 4 centenarians and 1 old healthy
volunteer showed detectable ANA levels. However, there
was no correlation between ANA level and the levels
of serum antibodies against YSATLRY and YSPTLFY
(Additional file 7: Figure S5). The antibodies that
recognize phosphorylated CTD of RPB1 might result
from the aging process, to which centenarians have
been exposed for a longer period than the average
population. To our knowledge, this is the first report
on autoreactive antibodies against RPB1 CTD in cen-
tenarians that occur at a higher frequency than in the
average population. The mechanism of how these
antibodies are generated and their role in human
(patho)physiology are interesting topics that we will
pursue in future research.
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antibody titer to YSATLRY (A) and YSPTLFY (B). Wells of a microtiter plate
were coated with either YSATLRYGGGSC or YSPTLFYGGGSC peptide
conjugated to BSA and blocked with 3 % BSA in PBS. Sera from individuals
diluted in 3 % BSA in PBS were added to the wells. After washing with
0.05 % PBST three times, the plates were incubated with HRP-conjugated
anti-human IgG antibodies. The washing steps were repeated three times.
2,2′-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid (ABTS) in 0.05 M citric
acid buffer (pH 4.0) and 1.0 % H2O2 were added to each well. OD was
measured at 405 nm with a microplate spectrophotometer. Asterisks
indicate five selected volunteers for further studies (Volunteer #7 = pAb 7,
Volunteer #11 = pAb 11, Volunteer #19 = pAb 19, Volunteer #47 = pAb 47,
and Volunteer #50 = pAb 50). (DOCX 150 kb)
Additional file 4: Figure S2. Competition enzyme immunoassay using
polyclonal antibodies (pAbs) with the peptide YSATLRY. Sera from five
volunteers showed reactivity to both YSATLRY and YSPTLFY, and pAbs
were purified using gels cross-linked with YSATLRYGGGSC. To confirm
pAb specificity, a competition enzyme immunoassay was performed. The
microtiter plate wells were coated with BSA-conjugated YSATLRYGGGSC
and blocked with 3 % BSA in PBS. A pre-mixture of pAbs and peptides
was added to each well. After washing with 0.05 % PBST three times,
plates were incubated with HRP-conjugated anti-human IgG antibodies.
Washing steps were repeated three times. ABTS in 0.05 M citric acid
buffer (pH 4.0) and 1.0 % H2O2 were added to each well. OD was measured
at 405 nm with a microplate spectrophotometer. LPCYTDHICYSSGGGS was
used as a control peptide. (DOCX 75 kb)
Additional file 5: Figure S3. Reactivity of scFv clones to peptides. (A)
YSATLRY, YSPTRFY, and three CTD peptides (one unphosphorylated and two
phosphorylated peptides) were synthesized and conjugated to BSA. (B)
Microtiter plates were coated with BSA-conjugated peptide and blocked with
3 % BSA in PBS. Then, mAbs (as scFv-human Fc fusion proteins) diluted in
3 % BSA in PBS were added to individual wells. After washing with 0.05 %
PBST three times, plates were incubated with HRP-conjugated anti-human
Fc-specific antibodies. Washing steps were repeated three times. ABTS in
0.05 M citric acid buffer (pH 4.0) and 1.0 % H2O2 were added to each well.
OD was measured at 405 nm with a microplate spectrophotometer. pAb 19
and normal human IgG were used as controls. (DOCX 168 kb)
Additional file 6: Figure S4. Immunoprecipitation of LoVo cell
lysates. LoVo cell lysates were incubated with either mAb 1 or mAb
2 (as scFv-human Fc fusion protein) conjugated to protein A beads.
After washing, the immunoprecipitate was subjected to NuPage
4–12 % Bis-Tris gel electrophoresis (Lane 2). The gel was stained with
Coomassie Brilliant Blue. Irrelevant scFv-human Fc fusion protein
(irrelevant mAb) was used as a control in immunoprecipitation experiments.
Lane 1 was loaded with the eluate of the mAb-conjugated gel without
incubation with LoVo cell lysates. Bands 1 and 2 were expected to be RPB1
and RPB2 isoform 1, respectively. (DOCX 103 kb)
Additional file 7: Figure S5. Correlation of ANA antibody index with
antibody reactivity to YSATLRY and YSPTLFY. The sera of 45 centenarian,
25 old, and 25 young volunteers were tested for ANA using an enzyme
immunoassay kit. Optical densities were converted to antibody index
according to the manufacturer’s instructions. (DOCX 48 kb)
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